Christophe Marchand

Membership in Scientific Societies and Professional Associations:

• 2007 to present: Steering Committee of the Center for Excellence in HIV and Cancer Virology, NCI.

Reviewer for Scientific Journals

• Nucleic Acids Research
• The Journal of Biological Chemisty
• Plos One
• Molecular Cancer Therapeutics
• The Journal of Medicinal Chemistry
• British Journal of Cancer
• Expert Opinion on Investigational Drugs
• Expert Opinion on Drug Safety
• Expert Opinion on Therapeutic Patents
• Expert Review of Anti-infective Therapy
• Biochimie
• Molecular Pharmacology
• Bioorganic Medicinal Chemistry & Bioorganic Medicinal Chemistry Letters
• ASSAY and Drug Development Technologies

Membership in Reviewing Boards (grant application boards etc.)

• 2012: Contract Review Officer for NCI-120057a-TG for the data transfer and analysis of RNA sequencing data of all genes in the NCI-60 plus BR: MDA MB-468 cell lines.
• 2012: Advisor on a NCI Focus Panel for Modernizing NCI Orientation.
• 2011: Contract Review Officer for NCI-110091-MW for the analysis of the protein levels andpost-translational modifications for 104 proteins in the NCI-60 cancerous cell lines.
• 2011: Center for Drug Research and Development and Genome British Columbia Development Fund: Ad Hoc Grant Reviewer for an application on the Discovery of Tdp1 Inhibitors.

Invited Lectureships

• 2014: 10th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat, NCI, NIH: SS/SC Communications and Review of Professional Opportunities.
• 2013: 9th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat, NCI, NIH: SS/SC Communications, SS/SC Officers Transition and Professional Development Committee presentation
• 2012: 8th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat, NCI, NIH: Welcome Address from the SS/SC Organization New Chairs.
• 2011: 4th International Conference on Retroviral Integration, Siena, Italy: Novel HIV-1 integrase inhibitors targeting the interface of the N- and C-terminal domains and overcoming resistance to strand transfer inhibitors.
• 2011: 7th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat, NCI, NIH: SS/SC Professional Development Committee Initiatives.
• 2010: PerkinElmer AlphaScreen and AlphaLisa Technology Symposium, Gaithersburg, MD: “Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay.”
• 2010: 6th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat, NCI, NIH: SS/SC Professional Development Committee Presentation.
• 2009: 5th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat, NCI, NIH:“Quantitative high-throughput screening of the NIH Roadmap Molecular Libraries Small Molecule Repository (MLSMR) for the discovery of human tyrosyl DNA phosphodiesterase I (Tdp1) inhibitors.”
• 2008: Center for Excellence in HIV and Cancer Virology Think Tank, CCR, NCI, Bethesda, MD:“Mono and Bi-functional quinolinonyl diketo acid derivatives as novel HIV-1 integrase inhibitors.”
• 2006: HIV-1 Drug Resistance Program Think Tank, CCR, NCI-Frederick, MD: “Novel inhibitors identified by a new HIV-1 integrase high-throughput screen.”
• 2004: HIV-1 Drug Resistance Program Think Tank, CCR, NCI-Frederick, MD: “Novel peptides inhibitors ofHIV-1 integrase.”
• 2002: HIV-1 Drug Resistance Program Think Tank, CCR, NCI-Frederick, MD: “Inhibition of HIV-1integrase by ß–diketo acids.”
• 2001: Center for Cancer Research Symposium, NCI-Frederick, MD: “Inhibition of HIV-1integrase by ß–diketo acids.”
• 2000: Center for Cancer Research Symposium, NCI-Frederick, MD: “Inhibition of HIV-1integrase by lexitropsins.”
• 1997: Organic and Biological Chemistry Journeys, Institut Curie, Paris, France: “Design of atriple-helix-specific cleaving reagent.”
• 1997: Young Researchers Forum of the French Molecular Biology Society, Corte, France: “New insights in the rational design of DNA triple helix specific ligands.”
• 1996: Young Researchers Forum of the French Molecular Biology Society, Poitiers, France: “New insights in the rational design of DNA triple helix specific ligands.”
• 1995: Young Researchers Forum of the French Molecular Biology Society, Grenoble, France: “Rational conception of switch oligonucleotides to extend the recognition sequences for DNA triple helix formation.”
• 1994: Young Researchers Forum of the French Molecular Biology Society, Reims, France: “Recognition sequence extension for DNA triple helix formation.”

Chairpersonships

• 2010: The Center for Excellence in HIV and Cancer Virology Fall Think Tank Meeting, NCI, NIH, Bethesda, MD:
• 1996: Young Researchers Forum of the French Molecular Biology Society, Poitiers, France: “New insights in the rational design of DNA triple helix specific ligands.”
• 1995: Young Researchers Forum of the French Molecular Biology Society, Grenoble, France: “Rational conception of switch oligonucleotides to extend the recognition sequences for DNA triple helix formation.”
• 1994: Young Researchers Forum of the French Molecular Biology Society, Reims, France: “Recognition sequence extension for DNA triple helix formation.”

Scientific Community Activities:
•Academic appointments:

• From 1995 to 1997: Staff teacher: Molecular DNA Footprinting. Master in “Biological Activities of Natural Products”, Muséum National d'Histoire Naturelle, Paris, France.
• From 1995 to 1997: Staff teacher: Molecular Biology, Educational Entertainment, Grande Galerie de l’Evolution, Muséum National d'Histoire Naturelle, Paris, France.